To report an adverse event or product quality issue, please email us at reportnow@argenx.com or call us at 1-833-274-9411.
©2026 argenx | Disclaimer | Privacy Policy | Regulations | U.S. Supplemental Privacy Notice
argenx Case Studies:
Stories of Co-Creation and Hope
See how entrepreneurial science and a shared pursuit of better outcomes can bring real change to people’s lives.
The Power of Partnerships
Collaboration accelerates our scientific discovery. With the IIP, we’re challenging conventions—and one another—to deliver life-changing treatments.
ARGX-115
TARGET: GARP
ABBV-151 (formerly ARGX-115) was designed as a humanized monoclonal antibody (mAb) inhibitor of GARP-TGF-β1 and is in development by AbbVie for the treatment of cancer.
ABBV-151 was built in collaboration with Prof. Sophie Lucas, M.D., Ph.D., a leader in checkpoint biology research since 1985.
ARGX-118
TARGET: Galectin-10
ARGX-118 was designed as a highly differentiated antibody against Galectin-10, the protein of Charcot-Leyden crystals. The crystals are a major contributor to severe asthma and the persistence of mucus plugs.
ARGX-118 was built in collaboration with Prof. Bart Lambrecht, M.D., Ph.D., who identified the first novel airway inflammation target in decades.
Adimanebart
TARGET: MuSK
Adimanebart (previously ARGX-119) emerged from our IIP. A humanized monoclonal antibody, it’s specifically designed to activate muscle-specific kinase (MuSK).
Developed in collaboration with Maartje Huijbers, Ph.D., Associate Professor and Research Group Leader at Leiden University Medical Center, and Steve Burden, Ph.D., during his tenure at NYU.
Efgartigimod
TARGET: FcRn
Efgartigimod (previously ARGX-113) was designed as a human IgG1 antibody Fcfragment, a natural ligand of the neonatal Fc receptor (FcRn). FcRn is known to extend half-life and availability of pathogenic IgG antibodies.
Efgartigimod has been engineered for increased affinity to FcRn and was built in collaboration with Prof. E. Sally Ward, Ph.D., who is a pioneer of FcRn biology.
Explore More
At argenx, every piece of the innovation story connects. See where it leads next.
Antibody Engineering
See how our platform technologies help optimize antibodies and amplify possibilities in immunology.
Co-Creation in Action
See what happens when our team takes promising leaps alongside leading scientists, physicians, and researchers.
Publications
Peer-reviewed publications that reflect our range of immunology innovation.
